<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04824261</url>
  </required_header>
  <id_info>
    <org_study_id>otomycosis</org_study_id>
    <nct_id>NCT04824261</nct_id>
  </id_info>
  <brief_title>Effectiveness of 4% Boric Acid in Distilled Water Versus Clotrimazole Solution in Otomycosis Patients.</brief_title>
  <official_title>Effectiveness of 4% Boric Acid in Distilled Water Versus Clotrimazole Solution in Otomycosis Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Otomycosis is a fungal infection that affects one, or occasionally both, of the ears. It&#xD;
      mostly affects people who live in warm or tropical areas. It also often affects people who&#xD;
      swim frequently, live with diabetes, or have other chronic medical and skin conditions. It is&#xD;
      a pathologic entity, with candida and aspergillus the most common fungal species. ]Various&#xD;
      predisposing factors include a humid climate, presence of cerumen, instrumentation of the&#xD;
      ear, increased use of topical antibiotics / steroid preparations, immune-compromised host,&#xD;
      patients who have undergone open cavity mastoidectomy and those who wear hearing aids with&#xD;
      occlusive ear mold. The infection is usually unilateral and characterized by inflammatory&#xD;
      pruritis, scaling and otalgia.Treatment recommendations have included local debridement,&#xD;
      local and systemic antifungal agents and discontinuation of topical antibiotics. Sometimes&#xD;
      otomycosis presents as a challenging disease for its long term treatment and follow up, yet&#xD;
      its recurrence rate remains high.&#xD;
&#xD;
      According to Thai National List of essential medicines for topical antifugal agents are:&#xD;
&#xD;
        -  acetic acid (2% in aqueous and 2% in 70% isopropyl alcohol)&#xD;
&#xD;
        -  boric acid (4% in distilled water)&#xD;
&#xD;
        -  gentian violet&#xD;
&#xD;
        -  clotrimazole ear drop. Some fungal infections such as Aspergillus may be resistant to&#xD;
           the usual ear drops. They may require oral medications.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Curative rate of otomycosis</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Otomycosis</condition>
  <arm_group>
    <arm_group_label>group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>randomized 50 otomycosis patients will receive Clotrimazol solution 1%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>randomized 50 otomycosis patients will receive 4%boric acid in distilled water</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clotrimazol solution 1%</intervention_name>
    <description>50 otomycosis randomized patients will receive Clotrimazol solution 1% The treatment will be locally applied for at least 2 weeks. All the patients will be followed up after the 1st week, 2nd week and after 1 month.</description>
    <arm_group_label>group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>4%boric acid in distilled water</intervention_name>
    <description>50 otomycosis randomized patients will receive 4%boric acid in distilled water The treatment will be locally applied for at least 2 weeks. All the patients will be followed up after the 1st week, 2nd week and after 1 month.</description>
    <arm_group_label>group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Symptomatic otomycosis.&#xD;
&#xD;
          -  Microscopic direct examination and/or culture positive for fungus.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  During usage of systemic antifungal drug&#xD;
&#xD;
          -  Allergic to 4% boric acid in distilled water or clotrimazole solution&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Maria H. Kamal</last_name>
    <phone>+201275589149</phone>
    <email>dr.m.hosny.ent@gmail.com</email>
  </overall_contact>
  <reference>
    <citation>Ho T, Vrabec JT, Yoo D, Coker NJ. Otomycosis: clinical features and treatment implications. Otolaryngol Head Neck Surg. 2006 Nov;135(5):787-91.</citation>
    <PMID>17071313</PMID>
  </reference>
  <reference>
    <citation>Mugliston T, O'Donoghue G. Otomycosis--a continuing problem. J Laryngol Otol. 1985 Apr;99(4):327-33.</citation>
    <PMID>4009029</PMID>
  </reference>
  <reference>
    <citation>Kaur R, Mittal N, Kakkar M, Aggarwal AK, Mathur MD. Otomycosis: a clinicomycologic study. Ear Nose Throat J. 2000 Aug;79(8):606-9.</citation>
    <PMID>10969470</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 27, 2021</study_first_submitted>
  <study_first_submitted_qc>March 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2021</study_first_posted>
  <last_update_submitted>March 27, 2021</last_update_submitted>
  <last_update_submitted_qc>March 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Maria Hosny Kamal Gendi</investigator_full_name>
    <investigator_title>resident doctor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Otomycosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clotrimazole</mesh_term>
    <mesh_term>Miconazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

